InMed Pharmaceuticals Inc.
- Filings
- 536
- Raw facts
- 6,570
- Metric values
- 2,009
Q2 2026+7.5% FY25 yoy
Q1 2027N/M FY26 yoy
Q1 2024N/M FY23 yoy
—derivedN/M FY24 yoy
Q1 2027N/M FY26 yoy
Q1 2027−79.6% FY26 yoy
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-06-30 | $4,942,633 | reported | |
| FY 2024 | 2024-06-30 | $4,597,730 | reported | |
| FY 2023 | 2023-06-30 | $4,135,561 | reported | |
| FY 2022 | 2022-06-30 | $1,365,755 revised | reported | |
| FY 2021 | 2021-06-30 | $1,904,013 | reported |
Segments
Segments
LineFY2023ShareChange
BayMedica-$1.21M—N/M
InMed-$6.74M—N/M
Total-$7.95M
Pharmaceutical preparations
InMed Pharmaceuticals Inc. is the 484th largest of the 554 covered companies the SEC files under this code, by total assets. SIC 2834
CompanyRevenueGrowthNet marginAssets
PTIXProtagenic Therapeutics, Inc.new$0.0——$2.3MSMNRSemnur Pharmaceuticals, Inc.———$2.0MHEPAHepion Pharmaceuticals, Inc.———$1.9MACUTAccustem Sciences Inc.———$1.6MATXIAvenue Therapeutics, Inc.$1.4M—207.2%$1.5MTCRTAlaunos Therapeutics, Inc.$5.0K50.0%83,520.0%$1.5M
MTRIInMed Pharmaceuticals Inc. (this company)———$1.3M
NRSNNeuroSense Therapeutics Ltd.———$1.0MPMHSPolomar Health Services, Inc.$648.2K1,002.0%1,650.8%$814.7KPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in total assets first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
InMed Pharmaceuticals Inc. · CIK 1728328 · Engraved from SEC EDGAR